Inhibikase Therapeutics (IKT) Institutional Ownership $1.91 -0.05 (-2.55%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)21TotalInstitutional Inflows(last 12 months)$78.37MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$476.14K Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2025 Jane Street Group LLC116,249$255K0.0%N/A0.156% 5/16/2025 Goldman Sachs Group Inc.166,025$364K0.0%+277.7%0.223% 5/16/2025 ADAR1 Capital Management LLC5,122,105$11.22M2.1%+0.4%6.890% 5/14/2025 Stonepine Capital Management LLC914,973$2.00M1.9%-19.2%1.231% 5/9/2025 Blair William & Co. IL155,953$342K0.0%+15.6%0.210% 5/6/2025 Y Intercept Hong Kong Ltd26,775$59K0.0%N/A0.036% 2/27/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/18/2025 Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/17/2025 Soleus Capital Management L.P.6,325,000$20.56M1.3%N/A9.119% 2/17/2025 Squarepoint Ops LLC28,411$92K0.0%N/A0.041% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025 Stonepine Capital Management LLC1,132,388$3.68M3.0%N/A1.633% 2/17/2025 OMERS ADMINISTRATION Corp54,600$177K0.0%N/A0.079% 2/17/2025 Millennium Management LLC142,209$462K0.0%N/A0.205% 2/17/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/17/2025 Fairmount Funds Management LLC6,125,000$19.91M2.0%N/A8.831% 2/17/2025 Blackstone Inc.2,070,684$6.73M0.0%N/A2.985% 2/17/2025 Caxton Corp16,393$53K0.3%N/A0.024% 2/14/2025 Nantahala Capital Management LLC2,190,000$7.12M0.3%N/A3.157% 2/14/2025 Northern Trust Corp64,011$208K0.0%N/A0.092% 2/14/2025 Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/14/2025 Stifel Financial Corp13,129$43K0.0%N/A0.019% 2/13/2025 Barclays PLC84,000$273K0.0%N/A0.121% 2/13/2025 ADAR1 Capital Management LLC5,103,005$16.59M3.3%N/A7.357% 2/12/2025 Geode Capital Management LLC322,878$1.05M0.0%+544.9%0.466% 2/12/2025 Blair William & Co. IL134,953$439K0.0%+7.0%0.195% 8/15/2024 Armistice Capital LLC589,575$713K0.0%N/A8.170% 11/15/2023 Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023 Barclays PLC11,455$41K0.0%N/A0.214% 8/8/2023 Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023 Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023 Blair William & Co. IL229,000$114K0.0%+27.9%0.817% 7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% 5/6/2022 Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022 Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022 Redmond Asset Management LLC122,682$182K0.1%N/A0.486% 2/14/2022 Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022 Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again.11/16/2021 Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021 Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021 Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021 Sabby Management LLC421,200$1.18M0.2%N/A4.157% 8/13/2021 Altium Capital Management LP109,749$307K0.1%N/A1.083% 8/13/2021 Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021 Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021 FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021 Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/21/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/18/2021 Millennium Management LLC11,224$67K0.0%N/A0.112% 5/18/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/17/2021 HRT Financial LP11,614$69K0.0%N/A0.115% (Data available from 1/1/2016 forward) IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, 22 institutional investors and hedge funds held shares of Inhibikase Therapeutics. The most heavily invested institutionals were Soleus Capital Management L.P. ($20.56M), Fairmount Funds Management LLC ($19.91M), ADAR1 Capital Management LLC ($11.22M), Nantahala Capital Management LLC ($7.12M), Blackstone Inc. ($6.73M), Stonepine Capital Management LLC ($2.00M), and Geode Capital Management LLC ($1.05M).Learn more on IKT's institutional investors. What percentage of Inhibikase Therapeutics stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics stock? Of the 21 institutional investors that purchased Inhibikase Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Soleus Capital Management L.P. ($6.33M), Fairmount Funds Management LLC ($6.13M), ADAR1 Capital Management LLC ($5.12M), Nantahala Capital Management LLC ($2.19M), Blackstone Inc. ($2.07M), Stonepine Capital Management LLC ($1.13M), and Armistice Capital LLC ($589.58K). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 24,595,987 shares in the last 24 months. This purchase volume represents approximately $78.62M in transactions. Which Inhibikase Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), Stonepine Capital Management LLC ($217.42K), and Hamilton Lane Advisors LLC ($69.02K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 596,931 shares in the last 24 months. This volume of shares sold represents approximately $2.40M in transactions. Related Companies ORIC Major Shareholders GHRS Major Shareholders TSHA Major Shareholders KROS Major Shareholders BCYC Major Shareholders IOVA Major Shareholders UPB Major Shareholders MNMD Major Shareholders DNTH Major Shareholders KURA Major Shareholders This page (NYSE:IKT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
